A method of manufacturing a granulated vaccine against newcastle disease of birds for oral administration

 

(57) Abstract:

The invention is intended for the production of biological preparations for immunization of poultry against Newcastle disease. In the fluidized bed of powder lactose to form granules. They sprayed the biomaterial containing vaccine strain of Newcastle disease virus. High speed drying in a sparing mode allows you to save without changing the basic immunobiological properties of Newcastle disease virus. The invention improves the manufacturability and performance of the method of manufacturing a granulated lactose vaccine against Newcastle disease of birds. table 1.

The invention relates to the field of veterinary Virology, namely the production of biological preparations for immunization of poultry against Newcastle disease.

Currently developed and implemented in the veterinary practice dry VirusWall against Newcastle disease of birds for oral immunization. These vaccines are used alone or in mixture with forage for birds. Granular form such drugs improves working conditions in the manufacturing process and the use of vaccines, provides good palatability bird.

5,0- 106,0EID50/g begins to decrease after 4 weeks of storage at 4oC.

Developed granulated lactose vaccine against Newcastle disease for oral vaccination of chickens in small farms (Veter. Environ. - 1995. - Vol. 46, N 1/3. - p. 47-53). The method of obtaining the vaccine is freeze-drying of biomaterial containing vaccine strain of Newcastle disease virus (strains V4 and Roakin), the inclusion of lyophilized virus in the mix for the production of granules containing lactose, and the formation of granules. The process of making vaccines a long, laborious, stage require different hardware equipment.

The aim of the invention is to improve the manufacturability and performance of the method of manufacturing a granulated lactose vaccine against Newcastle disease of birds for oral administration.

This goal is achieved by the fact that in the fluidized bed of powder of asle.

High speed drying in a sparing mode allows you to save without changing the basic immunobiological properties of Newcastle disease virus.

The manufacturing process of the vaccine is carried out on equipment granulation and drying in the fluidized bed.

Examples of specific performance.

Example 1. 200 g of lactose powder is placed in the apparatus granulation and drying in the fluidized bed (laboratory model) and granularit 40% solution of lactose to achieve a particle size of 2-3 mm, the temperature of the layer is maintained in the range of 38 - 40oC, solution - 20 - 22oC. the Pressure of compressed air to the injector is 0,18 - 0,20 MPa.

For the preparation of technical liquids mix 100 ml allantoine fluid embryos infected PCs "Bor-74 VGNKI" virus Newcastle disease, activity of 9.50 - 9,75 lg EID50/ml with 50 ml of 20% aqueous solution of peptone and 50 ml of 40% aqueous solution of lactose. In the granulator load 200 g lactose agglomerates and sprayed onto 200 ml of the fluid with a temperature of 20 - 22oC when the temperature of the layer 30 - 32oC and the pressure at the nozzle 0,18 - 0,20 MPa. After the spray dried for 20 minutes at a temperature of 30 - 32oC.

And what remained unchanged during the 2 weeks when (25 1oC, at 4 - 6oC - within six months. The vaccine was sterile against bacterial and fungal microflora.

Example 2. 150 g of lactose powder granularit in the apparatus of granulation and drying in the fluidized bed (laboratory model) 40% solution of lactose to obtain a particle size of 2 to 3 mm at a temperature of layer 38 to 40oC, solution - 20 - 22oC, the pressure of compressed air to the injector 0,18 - 0,20 MPa.

For the preparation of technical liquids mix 75 ml vaccinated material (allatoona fluid of infected PCs "La Sota virus Newcastle disease chick embryos) with the activity of 9.75 - 10,00 lg EID50/ml with 25 ml of 20% aqueous solution of peptone. The pellet was placed 150 g of lactose agglomerates and sprayed on 100 ml of the fluid with a temperature of 20 - 22oC when the temperature of the layer 30 - 32oC and the air pressure at the nozzle 0,18 - 0,20 MPa. After spraying the vaccine dried for 10 min at 30 - 32oC.

Activity derived vaccine - 9,25 - 9,50 lg EID50/,

The vaccine retained its activity without change in 2 weeks when (25 1)oC, at 4 - 6oC - within six months, was sterile in relation bakterielle 0,25 g per head vaccine protected 100% of chickens from infection by a strain of the T-53 virus Newcastle disease in 100% death of the birds in the control group.

Immunogenic properties of granulated lactose containing vaccines against Newcastle disease of birds received the existing and the proposed methods are presented in the table.

The use of the proposed method of manufacturing granulated lactose vaccine against Newcastle disease provides compared to existing the following benefits:

- the process of obtaining the vaccine is made on the same equipment;

- reduces the number of technological operations;

- dramatically reduces the duration of stages involving vaccinated material.

A method of manufacturing a granulated vaccine against Newcastle disease of birds for oral administration, including drying of biomaterial containing vaccine strain of Newcastle disease virus, mixed with the lactose and the formation of granules, characterized in that the pre-powdered lactose granularit 40% solution at 38 - 40oC and the pressure of compressed air to the injector 0,18 - 0,20 MPa in the machine granulation and drying in the fluidized bed, and the target product is obtained by sputtering on the resulting product of biomaterial containing vaccine strain of Newcastle disease virus.

 

Same patents:

The invention relates to the field of medicine

The invention relates to the field of pharmacy and relates to dosage forms of derivatives of 5-intorimidazole
The invention relates to antidepressant drug DULOXETINE in the form of enteric granules

The invention relates to medicine

The invention relates to the field of medicine

The invention relates to medicine, specifically to new granules with controlled release, containing a core of inert material'm entwined layer containing the drug, and method of production thereof

The invention relates to the field of veterinary Virology, namely, the vaccine against Newcastle disease of birds, intended for oral administration

The invention relates to veterinary Virology and biotechnology, and in particular to methods of obtaining living culture vaccines against distemper, and can be used at the enterprises of biological industry

The invention relates to a method for producing high-performance dry VirusWall from strain La Sota against Newcastle disease for prophylactic immunization of hens and chickens in a safe and threatened by Newcastle disease industrial farms and individual farms) poultry

The invention relates to veterinary medicine and relates to a drug for treatment and prophylaxis of plague, proviruses enteritis and hepatitis dogs (immunogen")
The invention relates to veterinary Virology, namely attenuated canine distemper virus, and can be used in the manufacture of preparations for diagnostics and specific prophylaxis of diseases of fur-bearing animals and dogs caused by canine distemper virus

The invention relates to veterinary medicine and, in particular, to the treatment of infectious diseases of animals and humans, accompanied by encephalitis

The invention relates to biotechnology, in particular for the associated vaccine used for specific prophylaxis of viral enteritis, botulism, Pseudomonas and distemper

FIELD: veterinary medicine.

SUBSTANCE: vaccine has antigenic material produced from La-Sota strain reproduced in 9-10 days old SPF-hen embryos having infectious activity of at least 9.7 lg EID50/cm3 and hemagglutination activity equal to at least 1:512, protective medium and adjuvant of thymogen taken in effective proportions. The protective medium comprises 20% lactalbumin hydrolyzate solution and degreased milk in 1:5 proportion. The vaccine is produced by mixing its ingredients and with following preparation lyophilization. Ready vaccine is dry porous mass of light yellow color. The vaccine is applicable for carrying out specific prophylaxis. The vaccine is introduced as spray at a dose of 1 cm3/head.

EFFECT: high antigenic and immunogenic activity; no adverse side effects.

7 cl, 8 tbl

Up!